These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 16433307)

  • 1. [Pegylated interferon-alfa 2a with ribavirin in chronic viral hepatitis C (final report)].
    Juszczyk J; Baka-Cwierz B; Beniowski M; Berak H; Bolewska B; Boroń-Kaczmarska A; Cianciara J; Cieśla A; Dziambor A; Gasiorowski J; Gietka A; Gliwińska E; Gładysz A; Gonciarz Z; Halota W; Horban A; Inglot M; Janas-Skulina U; Janczewska-Kazek E; Jaskowska J; Jurczyk K; Knysz B; Kryczka W; Kuydowicz J; Lakomy EA; Logiewa-Bazger B; Lyczak A; Mach T; Mazur W; Michalska Z; Modrzewska R; Nazzal K; Pabjan P; Piekarska A; Piszko P; Sikorska K; Szamotulska K; Sliwińska M; Swietek K; Tomasiewicz K; Topczewska-Staubach E; Trocha H; Wasilewski M; Wawrzynowicz-Syczewska M; Wrodycki W; Zarebska-Michaluk D; Zejc-Bajsarowicz M
    Przegl Epidemiol; 2005; 59(3):651-60. PubMed ID: 16433307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy.
    Parise E; Cheinquer H; Crespo D; Meirelles A; Martinelli A; Sette H; Gallizi J; Silva R; Lacet C; Correa E; Cotrim H; Fonseca J; Paraná R; Spinelli V; Amorim W; Tatsch F; Pessoa M;
    Braz J Infect Dis; 2006 Feb; 10(1):11-6. PubMed ID: 16767309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics].
    Husa P; Slesinger P; Stroblová H; Svobodník A; Husová L
    Klin Mikrobiol Infekc Lek; 2008 Apr; 14(2):67-73. PubMed ID: 18756436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
    Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
    Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
    J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
    Mangia A; Ricci GL; Persico M; Minerva N; Carretta V; Bacca D; Cela M; Piattelli M; Annese M; Maio G; Conte D; Guadagnino V; Pazienza V; Festi D; Spirito F; Andriulli A
    J Viral Hepat; 2005 May; 12(3):292-9. PubMed ID: 15850470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment.
    Reddy KR; Shiffman ML; Morgan TR; Zeuzem S; Hadziyannis S; Hamzeh FM; Wright TL; Fried M
    Clin Gastroenterol Hepatol; 2007 Jan; 5(1):124-9. PubMed ID: 17196435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy.
    Sherman M; Yoshida EM; Deschenes M; Krajden M; Bain VG; Peltekian K; Anderson F; Kaita K; Simonyi S; Balshaw R; Lee SS;
    Gut; 2006 Nov; 55(11):1631-8. PubMed ID: 16709661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin.
    Snoeck E; Wade JR; Duff F; Lamb M; Jorga K
    Br J Clin Pharmacol; 2006 Dec; 62(6):699-709. PubMed ID: 17118125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea].
    Lee H; Choi MS; Paik SW; Kim JH; Kim DY; Lee JH; Koh KC; Yoo BC; Rhee JC; Song SM
    Korean J Hepatol; 2006 Mar; 12(1):31-40. PubMed ID: 16565604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4.
    Hasan F; Asker H; Al-Khaldi J; Siddique I; Al-Ajmi M; Owaid S; Varghese R; Al-Nakib B
    Am J Gastroenterol; 2004 Sep; 99(9):1733-7. PubMed ID: 15330911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alpha-2a plus ribavirin.
    Bain VG; Lee SS; Peltekian K; Yoshida EM; Deschênes M; Sherman M; Bailey R; Witt-Sullivan H; Balshaw R; Krajden M;
    Aliment Pharmacol Ther; 2008 Jul; 28(1):43-50. PubMed ID: 18397386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C.
    Younossi ZM; McCullough AC; Barnes DS; Post A; Ong JP; O'Shea R; Martin LM; Bringman D; Farmer D; Levinthal G; Mullen KD; Carey WD; Tavill AS; Ferguson R; Gramlich T
    Dig Dis Sci; 2005 May; 50(5):970-5. PubMed ID: 15906777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy and safety of peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C virus infection].
    Delić D
    Med Pregl; 2006; 59(9-10):415-9. PubMed ID: 17345816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant.
    Rendina M; Schena A; Castellaneta NM; Losito F; Amoruso AC; Stallone G; Schena FP; Di Leo A; Francavilla A
    J Hepatol; 2007 May; 46(5):768-74. PubMed ID: 17383045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.
    McHutchison J; Sulkowski M
    J Viral Hepat; 2008 Jul; 15(7):475-81. PubMed ID: 18363672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
    Ferenci P; Formann E; Laferl H; Gschwantler M; Hackl F; Brunner H; Hubmann R; Datz C; Stauber R; Steindl-Munda P; Kessler HH; Klingler A; Gangl A;
    J Hepatol; 2006 Feb; 44(2):275-82. PubMed ID: 16338019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
    Sullivan SD; Jensen DM; Bernstein DE; Hassanein TI; Foster GR; Lee SS; Cheinquer H; Craxi A; Cooksley G; Klaskala W; Pettit K; Patel KK; Green J
    Am J Gastroenterol; 2004 Aug; 99(8):1490-6. PubMed ID: 15307866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
    Sood A; Midha V; Hissar S; Kumar M; Suneetha PV; Bansal M; Sood N; Sakhuja P; Sarin SK
    J Gastroenterol Hepatol; 2008 Feb; 23(2):203-7. PubMed ID: 17645472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, open-label, multicenter study evaluating the efficacy of peginterferon alfa-2a versus interferon alfa-2a, in combination with ribavirin, in naïve and relapsed chronic hepatitis C patients.
    Nevens F; Van Vlierberghe H; D'Heygere E; Delwaide J; Adler M; Henrion J; Lenaerts A; Hendlisz A; Michielsen P; Bastens B; Brenard R; Laureys A;
    Acta Gastroenterol Belg; 2010; 73(2):223-8. PubMed ID: 20690560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.